{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125331","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.142781+00:00","generated_at":"2026-05-30T01:59:54.223365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organogenesis Q3 revenue up 6% to $115.2M, net income $12.3M vs $3.2M; updates FY guidance","bullets":["Net revenue $115.2M (+6% YoY); Advanced Wound Care $108.0M (+7%).","GAAP net income $12.3M ($0.09 diluted EPS) vs $3.2M ($0.02) YoY.","Adjusted EBITDA $13.4M, down from $16.0M; Non-GAAP operating income $7.1M vs $11.0M.","Cash $94.9M, net debt $62.1M; FY guidance: rev $455-480M, adj net income $6.7-18.4M.","CEO cites brand equity and work with policymakers on access solution."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125331","json":"https://secwatch.observer/filing/0000950170-24-125331.json","markdown":"https://secwatch.observer/filing/0000950170-24-125331.md","text":"https://secwatch.observer/filing/0000950170-24-125331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024125331/0000950170-24-125331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000095017024125331/orgo-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:59:54.223365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}